We compared the abilities of free and liposome-incorporated SalmoneUa minnesota wild-type lipopolysaccharide (LPS) and lipid A to activate peritoneal macrophages and induce lethal toxicity in mice. Incorporation of lipid A into multilamellar vesicles resulted in a 100-fold-decreased potency to prime macrophages for phorbol myristate acetate-triggered release of H202. In addition, liposome incorporation reduced the lethality of LPS Lipopolysaccharide (LPS), a component of the outer membrane of gram-negative bacteria, triggers many of the pathological sequelae of gram-negative sepsis, including shock, disseminated intravascular coagulation, tissue injury, and death (21, 37, 43) . Although the precise cellular and molecular mechanisms whereby LPS elicits these pathological events have not been elucidated, mononuclear phagocytes (monocytes and macrophages) appear to play a central role (16, 36, 47) . LPS induces many responses from macrophages, among which are the development of an enhanced respiratory burst capacity (24, 40) and the secretion of inflammatory mediators, including prostaglandins (46), colony-stimulating factors (52), interleukin-1 (IL-1) (12) and tumor necrosis factor alpha (cachectin) (TNF) (4, 32). Recently, TNF has been shown to reproduce the manifestations of septic shock when administered to experimental animals, indicating that it is a major mediator of endotoxininduced injury (1, 33, 39, 45, 53) .
We compared the abilities of free and liposome-incorporated SalmoneUa minnesota wild-type lipopolysaccharide (LPS) and lipid A to activate peritoneal macrophages and induce lethal toxicity in mice. Incorporation of lipid A into multilamellar vesicles resulted in a 100-fold-decreased potency to prime macrophages for phorbol myristate acetate-triggered release of H202. In addition, liposome incorporation reduced the lethality of LPS and lipid A at least 10-fold in dactinomycin-sensitized mice. Similar results were obtained with multilamellar liposomes delivered intravenously and when small unilamellar vesicles were employed. The observed difference in toxicity was not dependent on dactinomycin treatment, since a similar decrease was obtained with large doses of liposomal LPS in unsensitized mice. Control liposomes, prepared without LPS and lipid A, did not reduce the activities of the free compounds. The administration of a sublethal amount of liposomal LPS induced within 20 days, but not during the first week, tolerance to a subsequently injected lethal dose of free endotoxin. The latter observation suggests that early-phase tolerance is not the mechanism responsible for the reduced toxicity of liposomal LPS. These data show that liposomal LPS and lipid A have reduced endotoxic activity in vivo and are consistent with our hypothesis that a direct interaction of lipid A with appropriate plasma membrane components is necessary to efficiently trigger biologic responses. This interaction, however, is prevented by the stable insertion of LPS into the liposomal membrane.
Lipopolysaccharide (LPS), a component of the outer membrane of gram-negative bacteria, triggers many of the pathological sequelae of gram-negative sepsis, including shock, disseminated intravascular coagulation, tissue injury, and death (21, 37, 43) . Although the precise cellular and molecular mechanisms whereby LPS elicits these pathological events have not been elucidated, mononuclear phagocytes (monocytes and macrophages) appear to play a central role (16, 36, 47) . LPS induces many responses from macrophages, among which are the development of an enhanced respiratory burst capacity (24, 40) and the secretion of inflammatory mediators, including prostaglandins (46) , colony-stimulating factors (52) , interleukin-1 (IL-1) (12) and tumor necrosis factor alpha (cachectin) (TNF) (4, 32). Recently, TNF has been shown to reproduce the manifestations of septic shock when administered to experimental animals, indicating that it is a major mediator of endotoxininduced injury (1, 33, 39, 45, 53) .
In previous in vitro studies on the mechanisms of LPS action, we modified the interaction of LPS and lipid A (the active moiety of LPS) with macrophages by incorporating these compounds into the lipid bilayer of liposomes (phospholipid vesicles). By using this approach, it was demonstrated that the potency of LPS and lipid A as inducers of macrophage secretory (IL-1 and TNF), phagocytic, and tumoricidal activities is reduced 100-to 1,000-fold by liposome incorporation (9, 10) . Experiments performed with radiolabeled LPS revealed that this decreased potency of liposomal LPS was not a result of reduced cellular uptake (10) . These findings suggested that incorporation of LPS into the bilayer of liposomes prevents the interaction of the active lipid A moiety with key plasma membrane structures involved in signal transduction (9, 10 (10) . Control liposomes were prepared with sterile, pyrogenfree phosphate-buffered saline. To incorporate up to 20 p.g of wt LPS per ,imol of total liposomal lipid, our previously described dry method was used to make both MLV and SUV (10, 11) . To incorporate up to 100 ,ug of wt LPS per ,mol of total liposomal lipid and to prepare relatively large amounts of phospholipid vesicles, the dry method was slightly modified as follows. The liposomal lipid mixture in chloroform (100 ,umol of total lipid) was dried in borosilicate glass culture tubes (16-mm diameter) by rotary evaporation and high vacuum. Next, the lipids were suspended in 2 ml of water containing the desired amounts of wt LPS (2.5 to 10 mg). After being vortexed and heated at 40 to 45°C, the lipid suspension was sonicated for two 12-min periods with intermittent vortexing. The resulting opalescent solution was lyophilized overnight and suspended in 1.5 ml of phosphatebuffered saline. MLV and SUV were then prepared by vortexing (MLV) and sonication (SUV) (10, 11) . To avoid potential contamination of the liposome preparations with environmental endotoxins, no attempts were made to separate unincorporated lipid A or wt LPS from the liposomes. More than 99% of the added lipid A or wt LPS was incorporated into the phospholipid vesicles used in this study, as indicated by at least 100-fold-reduced clotting activity in the Limulus amoebocyte lysate assay (10, 11) .
Peritoneal macrophage H202 release. Groups of four to six mice were injected intraperitoneally (i.p.) with 0. saline were administered i.p. (0.5 ml) or intravenously (i.v.) (0.2 to 0.3 ml) in the tail. The liposomal lipid A and LPS preparations diluted in phosphate-buffered saline were injected i.p. or i.v. in volumes similar to those of the free compounds. In most experiments, the animals were sensitized with 550 ,ug of dactinomycin per kg of body weight (from Streptomyces species; Sigma) (2, 50). This dose of dactinomycin was used because it was not lethal for control mice in our system. Dactinomycin was dissolved in ethanol (1 mg/ml) and was diluted in saline prior to use. The final concentration was checked by measuring the A430 (50) and adjusted as necessary. Dactinomycin (0.5 ml) was injected i.p. within 20 min after the mice received the LPS or lipid A preparations. Deaths were recorded daily for 7 to 10 days. The cumulative mortality after 4 days was summated (deaths after 4 days rarely occurred).
RESULTS
Augmentation of peritoneal macrophage H202-releasing capacity by free and liposomal lipid A. In initial experiments, we compared the abilities of free and liposome-incorporated monophosphoryl lipid A to augment peritoneal macrophage H202-releasing capacity when injected i.p. into mice. Four days after injection, peritoneal macrophages were isolated, and PMA-triggered H202 release was measured. H202 release was studied as the parameter of macrophage activation because it can be determined within 90 min of cell harvest, thus reducing the influence of in vitro culture on cellular function. Free lipid A was a potent activator of macrophage H202-releasing capacity (Fig. 1) (Fig. 1) . The MLV used in this experiment contained phosphatidylserine, which has been (Fig. 2) . This effect was again not due to a liposome-mediated alteration in macrophage responsiveness to lipid A, since coinjection of control MLV with free lipid A did not alter the dose-response curve of free lipid A (Fig. 2) . Lethal Various amounts of free lipid A or lipid A incorporated into MLV were injected into mice (0.5 ,umol of total lipid), followed within 20 min by the administration of dactinomycin. Liposomal lipid A was 10-fold less toxic than either free lipid A or free lipid A simultaneously injected with control MLV (Table 2) In addition, the incorporation of lipid A into SUV (0.5 ,umol of lipid per mouse) also resulted in a 10-fold reduction in lethal toxicity (results not shown). The reduced toxicity of liposomal lipid A did not appear to be dependent on a particular lipid dose, since a similar reduction in potency was observed when MLV-incorporated lipid A was administered in a lipid dose of 2.5 i,mol per animal (Table 2 ).
Lethal toxicity of free and liposomal wt LPS in sensitized and normal mice. Smooth or wt LPS is a potential contaminant of liposomes prepared for pharmaceutical use. For this reason, we also studied the toxic properties of S. minnesota wt LPS incorporated into liposomes or mixed with preformed vesicle preparations. MLV-incorporated wt LPS injected i.p. into dactinomycin-sensitized mice was more than 10-fold less toxic than free wt LPS (Table 3) . Analysis of the LD50s revealed values of 0.05 jig for free LPS and 3.2 jig for liposomal LPS (44) . When the route of administration was changed from i.p. to i.v., a similar reduction in toxicity was observed (Table 3 ). This result was also obtained when SUV were used as carriers for i.v. LPS. Conversely, free LPS mixed with control MLV or SUV and injected either i.p. or i.v. was essentially as toxic as the free compound alone (Table 3) .
To investigate whether the observed difference in toxicity of liposome-associated versus free LPS was related to the dactinomycin treatment, we conducted experiments to assess the LD10o of liposomal versus free LPS in unsensitized mice. The LD10o for wt LPS was found to be 100 to 150 jig for unsensitized animals. Next, various amounts of LPS were incorporated into MLV (up to 100 ,ug/,mol of total lipid), and the vesicles were injected i.v. To administer large doses of liposomal LPS, it was necessary to use a relatively large amount of total liposomal lipid (20 ,umol fold less toxic (LD10J, 1,000 p.g) than free LPS or free LPS mixed with control vesicles (LD1IJ, 100 ,ug) ( Table 4) .
Induction of lethal tolerance by liposomal wt LPS. Single or multiple daily injections of a nontoxic dose of LPS can induce resistance or tolerance to the lethal effects of readministered endotoxin (25) . Two phases of tolerance can be distinguished. In mice, early-phase tolerance develops within 24 h and starts waning in the next few days. In contrast, late-phase tolerance, which is LPS type specific, requires several days to develop after a single injection of LPS (25) . Induction of early-phase tolerance could account for the reduced toxicity we observed with liposomal LPS. To test the possibility that gradual release of LPS from the liposomes induced early-phase tolerance, the following experiment was performed. Mice were injected with a sublethal dose of MLV-incorporated wt LPS and after different time periods reinjected with a lethal dose of free LPS. The administration of 200 p.g of free LPS 1 to 7 days after the injection of 200 jig of MLV-LPS resulted in death of all the animals (Table 5 ). In fact, these mice appeared more sensitive since death occurred within 24 h, whereas the controls died between 24 and 48 h. In contrast, when free LPS was administered 20 days after the liposomal form, complete tolerance was observed (Table 5 ). These mice also survived the administration of a second lethal dose (200 ,ug) of free LPS, given 14 days after the initial challenge dose (Table 5) . No survival was observed in the simultaneously injected control groups which had not been exposed to liposomal LPS. These results suggest that a sublethal dose of liposomal LPS is able to induce late-phase but not early-phase tolerance.
DISCUSSION
The data presented in this in vivo study indicate that the macrophage-activating potency and lethal toxicity of liposome-incorporated LPS or lipid A are reduced 100-and 10-fold, respectively. The liposome dose, vesicle type, and route of administration did not appear to influence this effect. The decreased activities of liposomal LPS and lipid A were also not due to an effect of the phospholipid vesicles themselves, since control liposomes administered together with the free compounds did not significantly alter the potency of the free compounds. In addition, we have previously demonstrated that the procedure used to incorporate LPS into liposomes does not result in inactivation of this bacterial component; LPS with normal biological activity can be recovered from these liposomal LPS preparations (11) .
Previously, we investigated the effect of liposome incorporation on the ability of LPS and lipid A to activate macrophages in vitro (9, 10) . These studies demonstrated that compared with the free compounds, vesicle-incorporated LPS was at least 100-fold less potent in inducing the tumoricidal state or the secretion of IL-1 and TNF or in stimulating Fc-receptor-mediated phagocytosis. Both free and liposomal LPS, however, became associated with the macrophages in comparable amounts and appeared to be internalized by the endocytic pathway. From these observations, we concluded that the direct interaction of the hydrophobic part of the lipid A moiety of LPS with plasma membrane components is needed to optimally activate these cells in vitro. Thus, due to the stable insertion of the hydrophobic lipid A moiety in the liposomal membrane, this direct interaction is prevented during the association of LPSor lipid A-containing vesicles with macrophages. Possibly, LPS initially interacts with specific lipid A-binding proteins, which have been recently demonstrated in the plasma membranes of macrophages (20) and splenocyte subpopulations (29) .
It is possible that the decreased in vivo potency of liposomal LPS observed in the present study is the result of abrogation of a necessary mode of interaction of lipid A with the macrophage plasma membrane. Although macrophages play a major role as effector cells for the LPS-induced (patho)physiological effects (16, 36, 47) , the in vivo interaction of liposomal LPS-containing liposomes with other LPSresponsive cells, such as B lymphocytes (35) The increased capacity of LPS-elicited peritoneal macrophages to produce reduced oxygen metabolites after being triggered by PMA or other secondary stimuli was initially observed by Johnston and co-workers (24) . In vitro, LPS can prime peritoneal macrophages directly for the increased production of oxygen metabolites (40) , but the mechanism by which LPS activates macrophages in vivo is probably more complex, involving both direct and indirect effects. Mediators induced by LPS likely contribute to the induction of the primed state. For instance, both TNF and gamma interferon are able to activate peritoneal macrophages for PMA-triggered secretion of H202 (13, 38) . Moreover, these cytokines have been shown to be produced in vivo after LPS administration (6, 26, 33) . In vitro, the direct interaction of LPS with mononuclear phagocytes stimulates TNF secretion (4, 32). Macrophages are necessary as accessory cells for the LPS-induced production of gamma interferon by T lymphocytes (27) . The reduced potency of vesicle-incorporated lipid A to prime peritoneal macrophages in vivo which was observed in this study is probably the result of the ineffective interaction of liposomal lipid A with macrophages and possibly other responsive cells.
Cytokines released from macrophages certainly play an important role in the pathogenesis of endotoxic shock. Although mortality from endotoxemia can be considered the integral effect of the large variety of LPS-induced responses (21, 37, 43) , macrophage-derived TNF appears to be a central mediator. The administration of recombinant TNF mimics LPS in the induction of different pathophysiological effects (1, 33, 39, 45, 53) , and passive immunization with anti-TNF antibodies protects mice and rabbits from endotoxin-induced death (5, 33). Other LPS-induced mediators are probably also required. For example, Kiener and co- workers demonstrated that treatment of mice with detoxified monophosphoryl and toxic diphosphoryl lipid A resulted in comparable TNF levels in the circulation, but only the diphosphoryl component was lethal (26) . In addition, both LPS and IL-1 synergize with TNF in the induction of lethal shock (48, 54, 55) . Other evidence also indicates the involvement of TNF and IL-1 in endotoxemia. Treatments that sensitize mice for LPS-induced lethality also render these animals hyperresponsive to the toxic effects of both TNF and IL-1 (3, 28, 56) . Given the important role of TNF and IL-1 in endotoxic shock and our previous observation that the secretion of these cytokines from macrophages in vitro was considerably reduced upon incorporation of LPS in liposomes, we conclude that impaired secretion of these mediators may contribute to the decreased in vivo toxicity of the liposomal form.
The finding that liposomal LPS did not induce early-phase tolerance indicates that this phenomenon probably does not play a significant role in the decreased toxicity of liposomal LPS. Recent reports suggest that TNF and IL-1 are also involved in the induction of early-phase endotoxin tolerance (15, 54, 56) . This suggests that the levels of TNF and IL-1 induced by liposomal LPS are probably not sufficient to induce early-phase tolerance. It is known that the protection observed during late-phase tolerance correlates with the presence of antibodies directed against the carbohydrate chain (O antigen) of LPS (25) . Since liposome-incorporated LPS has been shown to induce humoral immunity (8), the late tolerance observed in our study was probably also the result of the generation of specific antibodies, LPS-antibody complexes are thought to be less toxic due to neutralization and/or increased clearance by the host (42) .
In vivo, free LPS is possibly detoxified by both intravascular mechanisms and the phagocytic cells comprising the reticuloendothelial system (51) . Ultimately, most of the LPS seems to be processed by the liver, initially by the liver macrophages or Kupffer cells. Intravenously administered liposomes, irrespective of the presence of LPS as a constituent, are taken up mainly by the macrophages of the liver and the spleen (22, 49) . Within a few hours, i.p. injected liposomes also reach the blood circulation via the abdominal lymphatics and are subsequently cleared by the same tissues as i.v. administered vesicles (14, 22, 49 
